MX2023000165A - Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas. - Google Patents
Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas.Info
- Publication number
- MX2023000165A MX2023000165A MX2023000165A MX2023000165A MX2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A MX 2023000165 A MX2023000165 A MX 2023000165A
- Authority
- MX
- Mexico
- Prior art keywords
- fixed
- dose
- dose combination
- treating pulmonary
- mac
- Prior art date
Links
- 229940000425 combination drug Drugs 0.000 title abstract 5
- 230000002685 pulmonary effect Effects 0.000 title abstract 3
- 206010062207 Mycobacterial infection Diseases 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 title 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 title 1
- 201000008827 tuberculosis Diseases 0.000 title 1
- 229940126534 drug product Drugs 0.000 abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 4
- 208000033126 Colobomatous microphthalmia Diseases 0.000 abstract 3
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 abstract 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 abstract 3
- 229960002626 clarithromycin Drugs 0.000 abstract 3
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 abstract 3
- 229960004287 clofazimine Drugs 0.000 abstract 3
- 208000034367 isolated with coloboma microphthalmia Diseases 0.000 abstract 3
- 229960000885 rifabutin Drugs 0.000 abstract 3
- 208000032376 Lung infection Diseases 0.000 abstract 2
- 208000022155 mycobacterium avium complex disease Diseases 0.000 abstract 2
- 241000186367 Mycobacterium avium Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063046335P | 2020-06-30 | 2020-06-30 | |
| US202063046322P | 2020-06-30 | 2020-06-30 | |
| PCT/IB2021/000451 WO2022003421A2 (en) | 2020-06-30 | 2021-06-30 | Triple antibiotic fixed-dose combination products, dosing regimen, methods, and kits for treating pulmonary non-tuberculosis mycobacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000165A true MX2023000165A (es) | 2023-02-22 |
Family
ID=79032054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000165A MX2023000165A (es) | 2020-06-30 | 2021-06-30 | Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11590154B2 (https=) |
| EP (1) | EP4171546A4 (https=) |
| JP (1) | JP2023533472A (https=) |
| KR (1) | KR20230028502A (https=) |
| CN (1) | CN115768420A (https=) |
| AU (1) | AU2021298936A1 (https=) |
| BR (1) | BR112022026615A2 (https=) |
| CA (1) | CA3187031A1 (https=) |
| IL (1) | IL299287A (https=) |
| MX (1) | MX2023000165A (https=) |
| WO (1) | WO2022003421A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025026423A1 (en) * | 2023-08-02 | 2025-02-06 | Shenzhen Pharmacin Co., Ltd. | Compositions, their use and manufacture for treatment of gastrointestinal conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR012304A1 (es) | 1997-04-01 | 2000-10-18 | Borody Thomas J | Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos. |
| PT2247291T (pt) * | 2008-02-08 | 2019-02-01 | Red Hill Biopharma Ltd | Métodos e composições para tratamento de doença inflamatória do intestino |
| TWI573590B (zh) * | 2011-09-20 | 2017-03-11 | 雷希爾生藥有限公司 | 治療自體免疫疾病之組成物及方法 |
| US20180273573A1 (en) | 2015-10-01 | 2018-09-27 | Memorial Sloan-Kettering Cancer Center | Inhibitors of menaquinone biosynthesis |
| WO2017194734A1 (en) | 2016-05-13 | 2017-11-16 | Technische Universität München | Means and methods for treating mycobacterial diseases |
-
2021
- 2021-06-30 WO PCT/IB2021/000451 patent/WO2022003421A2/en not_active Ceased
- 2021-06-30 CN CN202180044988.XA patent/CN115768420A/zh active Pending
- 2021-06-30 CA CA3187031A patent/CA3187031A1/en active Pending
- 2021-06-30 AU AU2021298936A patent/AU2021298936A1/en active Pending
- 2021-06-30 EP EP21834321.8A patent/EP4171546A4/en not_active Withdrawn
- 2021-06-30 US US17/364,124 patent/US11590154B2/en active Active
- 2021-06-30 KR KR1020237002839A patent/KR20230028502A/ko active Pending
- 2021-06-30 JP JP2022580214A patent/JP2023533472A/ja active Pending
- 2021-06-30 MX MX2023000165A patent/MX2023000165A/es unknown
- 2021-06-30 IL IL299287A patent/IL299287A/en unknown
- 2021-06-30 BR BR112022026615A patent/BR112022026615A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11590154B2 (en) | 2023-02-28 |
| US20210401865A1 (en) | 2021-12-30 |
| EP4171546A4 (en) | 2024-03-13 |
| CA3187031A1 (en) | 2022-01-06 |
| IL299287A (en) | 2023-02-01 |
| EP4171546A2 (en) | 2023-05-03 |
| BR112022026615A2 (pt) | 2023-01-24 |
| CN115768420A (zh) | 2023-03-07 |
| WO2022003421A3 (en) | 2022-03-17 |
| JP2023533472A (ja) | 2023-08-03 |
| WO2022003421A2 (en) | 2022-01-06 |
| KR20230028502A (ko) | 2023-02-28 |
| AU2021298936A1 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jensen et al. | Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients | |
| Hooper | New uses for new and old quinolones and the challenge of resistance | |
| McCARTHY | Pyostomatitis vegetans: report of three cases | |
| Legent et al. | A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. | |
| Martin et al. | Levofloxacin and sparfloxacin: new quinolone antibiotics | |
| NZ552047A (en) | Method of treatment of endobronchial infections | |
| EP1243267A3 (en) | Amoxycillin and clavulanate containing pharmaceutical formulation | |
| CO5021201A1 (es) | Metodo de tratar infecciones bacterianas causadas potencial- mente por streptococcus pneumoniae | |
| Blomgren et al. | Fluconazole versus nystatin in the treatment of oral candidosis | |
| Khozeimeh et al. | Comparative evaluation of ketoconazole tablet and topical ketoconazole 2% in orabase in treatment of Candida-infected denture stomatitis | |
| Galgiani et al. | Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole | |
| Weiss et al. | Acute nonspecific lung abscess: a controlled study comparing orally and parenterally administered penicillin G | |
| MX2023000165A (es) | Productos de combinacion de dosis fijas de tres antibioticos, regimen de dosificacion, metodos y kits para tratar infecciones micobacterianas pulmonares no tuberculosas. | |
| DINSMOOR et al. | A randomized, double-blind, placebo-controlled trial of oral antibiotic therapy following intravenous antibiotic therapy for postpartum endometritis | |
| Hooper et al. | Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects | |
| Raz et al. | Double-blind study comparing 3-day regimens of cefixime and ofloxacin in treatment of uncomplicated urinary tract infections in women | |
| AU777508B2 (en) | Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate | |
| KR20060040603A (ko) | 아스코르브산을 포함하는 진균성 중복감염들 및 진균성재발들의 치료용 약학적 조성물들 | |
| EP4494700A3 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| Pankhurst et al. | Prophylactic application of an intra-alveolar socket medicament to reduce postextraction complications in HIV-seropositive patients | |
| Brook et al. | Eradication of pathogens from the nasopharynx after therapy of acute maxillary sinusitis with low-or high-dose amoxicillin/clavulanic acid | |
| Stillerman | Comparison of cephaloglycin and penicillin in streptococcal pharyngitis | |
| Sackel et al. | In vitro activity of p-hydroxybenzyl penicillin (penicillin X) and five other penicillins against Neisseria gonorrhoeae: comparisons of strains from patients with uncomplicated infections and from women with pelvic inflammatory disease | |
| CN103596565A (zh) | 塞克硝唑在口腔感染治疗中的应用 | |
| Jackson | Prevention of rheumatic fever: A comparative study of clindamycin palmitate and ampicillin in the treatment of group A beta hemolytic streptococcal pharyngitis |